MBAM
HBIO icon

Mink Brook Asset Management’s Harvard Bioscience HBIO Stock Holding History

Mink Brook Asset Management’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$205K Buy
+33,369
New +$200K 0.09% 48

Other funds holding HBIO

WCM
Weber Capital Management San Francisco, California $118M AUM
MIM
Meros Investment Management Dallas, Texas $315M AUM 58.44% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mink Brook Asset Management's HBIO Position: Q2 2026 in Review

Mink Brook Asset Management opened a new position in Harvard Bioscience (HBIO) in Q2 2026: 33,369 shares worth $205K. The stake represents 0.09% of the portfolio and ranks #48 among its holdings.

34 funds tracked by Wall St. Rank hold HBIO as of Q2 2026.

  • Mink Brook Asset Management held 33,369 shares of Harvard Bioscience worth $205K as of Q2 2026.
  • Harvard Bioscience was a new Mink Brook Asset Management position in Q2 2026.
  • Harvard Bioscience made up 0.09% of Mink Brook Asset Management's portfolio in Q2 2026, its #48 holding.
  • 34 funds tracked by Wall St. Rank held Harvard Bioscience as of Q2 2026.

Based on Mink Brook Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.